30 Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. NCI sponsored international Working group. J Clin Oncol 1999;17:1244. 31 Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ- C30: a quality- of- life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. 32 Alexandrov LB, Nik- Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–21. 33 King GW, Grozea PC, Eyre HJ, et al. Neoantigen response in patients successfully treated for lymphoma. A southwest Oncology Group study. Ann Intern Med 1979;90:892–5. 34 Martin SD, Brown SD, Wick DA, et al. Low mutation burden in ovarian cancer may limit the utility of Neoantigen- Targeted vaccines. PLoS One 2016;11:e0155189. 35 Hu Z, Leet DE, Allesøe RL, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 2021;27:515–25. 36 Yamamoto TN, Kishton RJ, Restifo NP . Developing neoantigen- targeted T cell- based treatments for solid tumors. Nat Med 2019;25:1488–99. 37 Wedén S, Klemp M, Gladhaug IP , et al. Long- Term follow- up of patients with resected pancreatic cancer following vaccination against mutant K- ras. Int J Cancer 2011;128:1120–8. 38 Alspach E, Lussier DM, Miceli AP , et al. MHC- II neoantigens shape tumour immunity and response to immunotherapy. Nature 2019;574:696–701. 39 Marty Pyke R, Thompson WK, Salem RM, et al. Evolutionary pressure against MHC class II binding cancer mutations. Cell 2018;175:e13:416–28. 40 Yarchoan M, Johnson BA, Lutz ER, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017;17:209–22.